All In Biotech

Drug Trial Radar · NCT04656561

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) - The ARCHER Study

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

270

Actual

Start

Feb 26, 2021

Primary completion

Mar 28, 2023

Study completion Sep 13, 2023

Sponsor

Lead sponsor
Annexon, Inc.Industry
Sponsor type
Industry
First posted
Dec 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.

Conditions

  • Geographic Atrophy

Interventions

  • ANX007Drug

    Form: solution for injection; Route of Administration: IVT

  • Sham comparatorOther

    Form and Route of Administration: pressure to mimic IVT injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Change (Slope) From Baseline to Month 12 in GA Lesion AreaTime frame: Baseline to Month 12

Locations

53 sites in 3 countries. Site status is shown where the registry gives one.

  • Site 5

    Phoenix, Arizona

  • Site 31

    Bakersfield, California

  • Site 2

    Beverly Hills, California

  • Site 19

    Mountain View, California

  • Site 23

    Pasadena, California

  • Site 37

    Poway, California

  • Site 17

    Sacramento, California

  • Site 18

    Santa Ana, California

  • Site 33

    Walnut Creek, California

  • Site 39

    Waterford, Connecticut

  • Site 12

    Fort Myers, Florida

  • Site 53

    Jacksonville, Florida

  • Site 26

    Pensacola, Florida

  • Site 16

    Pinellas Park, Florida

  • Site 43

    Sarasota, Florida

  • Site 28

    St. Petersburg, Florida

  • Site 6

    Winter Haven, Florida

  • Site 42

    Augusta, Georgia

  • Site 11

    Lexington, Kentucky

  • Site 1

    Hagerstown, Maryland

  • Site 41

    Hagerstown, Maryland

  • Site 36

    Boston, Massachusetts

  • Site 3

    Springfield, Massachusetts

  • Site 29

    Royal Oak, Michigan

  • Site 10

    Reno, Nevada

  • Site 38

    Bloomfield, New Jersey

  • Site 9

    Cherry Hill, New Jersey

  • Site 30

    Albuquerque, New Mexico

  • Site 20

    Asheville, North Carolina

  • Site 52

    Cleveland, Ohio

  • Site 13

    Edmond, Oklahoma

  • Site 40

    Eugene, Oregon

  • Site 27

    Philadelphia, Pennsylvania

  • Site 15

    Abilene, Texas

  • Site 4

    Austin, Texas

  • Site 24

    Bellaire, Texas

  • Site 34

    Burleson, Texas

  • Site 21

    Dallas, Texas

  • Site 32

    Fort Worth, Texas

  • Site 22

    Fort Worth, Texas

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.